Reportlinker Adds Allergan Inc.: PharmaVitae Profile

Look up the PowerRating of AGN and see how it has performed over the past week as well as the current proprietary PowerRating.

NEW YORK, Oct 16, 2009 /PRNewswire via COMTEX/ -- AGN | Quote | Chart | News | PowerRating -- Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds Allergan Inc.: PharmaVitae Profile

http://www.reportlinker.com/p0155102/Reportlinker-Adds-Allergan-Inc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Allergan's performance against key rivals in the prescription pharmaceutical sector

*Assess how the key Botox franchise stands up to the global recession and the arrival of further competitors

*Analyze the impact of Allergan's acquisition of Esprit Pharma in 2007, namely its movement into the urology therapy market

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Allergan: PharmaVitae forecasts at a glance 8

Strategic insight 9

Allergan is highly dependent upon sales of Botox 9

Botox plays a central role in Allergan's synergistic expansion 10

SWOT analysis 12

Strengths 12

Weaknesses 13

Opportunities 14

Threats 15

Table of Contents 16

Table of figures 18

Chapter 3 Quarterly news update 19

Product developments 19

Deals and alliances 20

Product deals 20

Technology deals 21

M&A activity 21

Company announcements 22

Future product milestones 22

Chapter 4 Company introduction 23

Key findings 23

Background 24

Key corporate developments 24

M&A history 25

Acquired by SmithKline Beckman 25

Allergan spun-out from SmithKline Beckman 26

Acquisition of Oculinum 26

Divestment of Allergan Humphrey 26

Divestment of contact lens businesses 26

Five acquisitions were made in and around 1995 26

Allergan Specialty Therapeutics spun-out 26

Allergan Specialty Therapeutics re-acquired 26

Bardeen Sciences set-up 26

Advanced Medical Optics spun-out 27

Bardeen Sciences acquired 27

Oculex acquired 27

Acquistition of Inamed 27

Groupe Corneal Laboratoires acquired 27

EndoArt acquired 27

Acquisition of Esprit Pharma 28

Current corporate structure 29

Pharmaceuticals 29

Allergan Medical 29

Chapter 5 Company sales 31

Key findings 31

Prescription pharmaceutical sales and growth rate analysis, 2002-14 32

Product analysis 34

Product analysis, 2002-08 35

Product analysis, 2008-14 37

Therapy area analysis 40

Geographic analysis 43

Launch/core/expiry analysis 45

Explanation of launch/core/expiry analysis 45

Launch analysis, 2008-14 46

Core analysis, 2008-14 49

Expiry analysis, 2008-14 50

Launch/core/expiry configuration, 2008-14 52

Molecule type analysis 53

Externalization analysis 55

Chapter 6 Company financials 57

Key findings 57

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 58

Operating costs and profit analysis 60

Operating costs and profit analysis, 2002-08 61

Operating cost ratio and profit margin analysis, 2002-08 62

Operating cost ratio and profit margin analysis, 2008-14 63

Operating costs and profit analysis, 2008-14 64

Chapter 7 Key products and competitors 66

Key findings 66

Overview 67

Central nervous system 68

Botox 68

Overview 68

Sales forecast 69

Other (ophthalmology) 71

Restasis 71

Overview 71

Sales forecast 72

Lumigan franchise 73

Overview 73

Sales forecast 74

Alphagan franchise 76

Overview 76

Sales forecast 77

Ozurdex 79

Overview 79

Sales forecast 80

Ozurdex offers significant benefits over the standard of care 81

Other (skin care) 82

Latisse 82

Overview 82

Sales forecast 83

Chapter 8 Appendix 84

R&D pipeline 84

Reconciliation with reported figures 85

References 86

Abbreviations 86

Exchange rates 87

About Datamonitor 88

About Datamonitor Healthcare 88

Datamonitor consulting 88

Disclaimer 90

List of Tables

Table 1: Allergan - PharmaVitae forecasts at a glance 8

Table 2: Allergan key product developments, Q1-Q2 2009 19

Table 3: Allergan product deals and alliances, Q1-Q2 2009 20

Table 4: Allergan technology deals and alliances, Q1-Q2 2009 21

Table 5: Allergan M&A activity, Q1-Q2 2009 21

Table 6: Allergan company announcements, Q1-Q2 2009 22

Table 7: Allergan future product milestones, 2009-11 22

Table 8: Allergan product portfolio overview ($m), 2002-08 35

Table 9: Allergan product portfolio overview ($m), 2008-14 37

Table 10: Allergan prescription pharmaceutical sales by therapy area ($m), 2008-14 42

Table 11: Allergan prescription pharmaceutical sales by geographic region ($m), 2008-14 44

Table 12: Allergan launch portfolio overview ($m), 2008-14 46

Table 13: Allergan core portfolio overview ($m), 2008-14 49

Table 14: Allergan expiry portfolio overview ($m), 2008-14 50

Table 15: Allergan prescription pharmaceutical sales by molecule type ($m), 2008-14 54

Table 16: Allergan prescription pharmaceutical sales by source ($m), 2008-14 56

Table 17: Total Allergan sales by business unit ($m), 2002-08 58

Table 18: Allergan operating revenue/cost analysis ($m), 2002-08 61

Table 19: Allergan operating cost ratio analysis (% of total revenues), 2002-08 62

Table 20: Allergan operating cost ratio analysis (% of total revenues), 2008-14 63

Table 21: Allergan operating revenue/cost analysis ($m), 2008-14 64

Table 22: Key products overview 67

Table 23: Botox: overview 68

Table 24: Botox: sales forecast ($m), 2008-14 69

Table 25: Restasis: overview 71

Table 26: Restasis: sales forecast ($m), 2008-14 72

Table 27: Lumigan franchise: overview 73

Table 28: Lumigan franchise: sales forecast ($m), 2008-14 74

Table 29: Alphagan franchise: overview 76

Table 30: Alphagan franchise: sales forecast ($m), 2008-14 77

Table 31: Ozurdex: overview 79

Table 32: Ozurdex: sales forecast ($m), 2008-14 80

Table 33: Latisse: overview 82

Table 34: Latisse: sales forecast ($m), 2008-14 83

Table 35: Allergan's R&D pipeline (Phase I-registration) 84

Table 36: Total Allergan revenue by business unit and product line ($m), 2002-08 85

Table 37: Exchange rates, 2009 87

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Allergan's financial performance ($m), 2002-14 7

Figure 4: Allergan prescription pharmaceutical sales ($m), 2002-14 9

Figure 5: The central role of Botox in Allergan's strategic moves 10

Figure 6: Allergan SWOT analysis 12

Figure 7: Allergan's M&A history 25

Figure 8: Current corporate structure 29

Figure 9: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 32

Figure 10: Key product sales ($m), 2002-14 34

Figure 11: Allergan key sales growth drivers and resistors ($m), 2002-08 36

Figure 12: Allergan key sales growth drivers and resistors ($m), 2008-14 38

Figure 13: Allergan prescription pharmaceutical sales by therapy area ($m), 2002-14 40

Figure 14: Allergan prescription pharmaceutical sales by geographic region ($m), 2002-14 43

Figure 15: Allergan launch/core/expiry configuration ($m), 2008-14 52

Figure 16: Allergan prescription pharmaceutical sales by molecule type ($m), 2002-14 53

Figure 17: Allergan prescription pharmaceutical sales by source ($m), 2002-14 55

Figure 18: Allergan operating revenue/cost analysis ($m), 2002-14 60

Figure 19: Mechanisms by which current treatments reduce intraocular pressure 75

To order this report:

Reportlinker Adds Allergan Inc.: PharmaVitae Profile

http://www.reportlinker.com/p0155102/Reportlinker-Adds-Allergan-Inc-PharmaVitae-Profile.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)-652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker

http://www.reportlinker.com

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index